Title: Changes in angiotensin-converting enzyme activity in lungs damaged by the pyrrolizidine alkaloid monocrotaline.
Authors: Lafranconi, W M; Huxtable, R J
Published In Thorax, (1983 Apr)
Abstract: Administration of monocrotaline, a pyrrolizidine alkaloid, to male Sprague-Dawley rats for up to three weeks increased dry lung weights by 64% and reduced the specific activity of lung angiotensin-converting enzyme activity by 64%. When the total activity per lung is calculated, however, there is no significant difference between control and monocrotaline-treated animals. The decrease in specific activity is due to increase in total lung protein (52% above control) and not to an actual reduction in the total angiotensin-converting enzyme activity in th lung.
PubMed ID: 6306859
MeSH Terms: Animals; Lung/drug effects; Lung/enzymology*; Male; Monocrotaline; Organ Size/drug effects; Peptidyl-Dipeptidase A/metabolism*; Proteins/metabolism; Pyrrolizidine Alkaloids/pharmacology*; Rats; Rats, Inbred Strains